Loading…
StockAnalyzerLoading…
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides NovoPen 6 and NovoPen Echo Plus, smart insulin pens; Dose Check, an insulin dose guidance application; growth hormone pens and injection needles; and Wegovy pill an oral glucagon-like peptide-1 (GLP-1) receptor agonist therapy for weight management. The company has a collaboration with Anthropic accelerate the development of new medicines and advance AI-driven software development. It operates in Europe, Canada, the United States, Japan, Korea, Oceania, Southeast Asia, Mainland China, Hong Kong and Taiwan, Latin America, the Middle East, and Africa. It has a strategic collaboration with Orbis Medicines to discover and develop oral macrocycle therapeutics for cardiometabolic diseases. The company was formerly known as Novo Industri A/S and changed its name to Novo Nordisk A/S in April 1989. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Novo Nordisk A/S, doing business as Novo, is a Danish multinational pharmaceutical company. Novo manufactures and markets pharmaceutical products and services, primarily obesity and diabetes medications and devices. The corporation was created in 1989, through a merger of two Danish pharmaceutical companies, which date back to the 1920s. Wikipedia ↗
Founders: August Kongsted, August Krogh, Hans Christian Hagedorn, Marie Krogh · Headquarters: Bagsværd
www.novonordisk.com ↗| Mr. Karsten Munk Knudsen | Executive VP, CFO & Member of the Management Board | 54 | 2,584,764 DKK |
| Mr. Maziar Mike Doustdar B.A. | President, CEO & Member of the Management Board | 55 | — |
| Dr. Martin Holst Lange | EVP of R&D, Chief Scientific Officer and Member of the Management Board | 55 | 1,833,379 DKK |
| Ms. Tania Sabroe | EVP of People, Organisation and Corporate Affairs & Member of Management Board | 48 | — |
| Ms. Thilde Hummel Bogebjerg | Executive VP of Enterprise IT & Quality and Member of Management Board | 43 | — |
| Mr. John F. Kuckelman | SVP, Group General Counsel, Global Legal, IP & Security and Member of Management Board | 53 | — |
| Mr. Emil Kongshoej Larsen | EVP of International Operations & Member of Management Board | 50 | — |
| Ms. Elin Jager | SVP, Chief of Staff to CEO, Corporate Strategy & Sustainability and Member of Management Board | 39 | — |
| Mr. Jamey Millar | Executive VP of US Operations & Member of Management Board | 57 | — |
| Ms. Hong Chow | Executive VP of Product & Portfolio Strategy and Member of Management Board | 54 | — |
CEOs over time (Wikidata): Lars Fruergaard Jørgensen (2017–), Lars Rebien Sørensen (2000–2016), Mike Doustdar (?–)
| Year | Buybacks | Dividends | Acquisitions |
|---|---|---|---|
| 2021 | — | — | — |
| 2022 | 24,086 | 25,303 | 7,075 |
| 2023 | 29,924 | 31,767 | -0 |
| 2024 | 20,181 | 44,140 | 82,163 |
| 2025 | 1,388 | 51,763 | -0 |
Shares outstanding since 2017: -8.9% 4.85 bn → 4.41 bn. Fewer shares — the company buys them back and each holder owns more.
Source: Wikidata. Year — when the company joined the group (acquired or created).
| Novo Nordisk (Switzerland) | — |
| Novo Nordisk (United States) | — |
| Novo Nordisk (Algeria) | — |
| Novo Nordisk (Germany) | — |
| Novo Nordisk s.r.o. | — |
| NNE A/S | — |